Cemat A/S
No. 9/2025 - Managers’ transactions
No. 9/2025 - Managers’ transactions
Nasdaq Copenhagen
Nikolaj Plads 6
DK-1067 Copenhagen K
Copenhagen, 25 March 2025
ANNOUNCEMENT no. 9/2025
Managers’ transactions
Pursuant to Article 19 of the market abuse regulation Cemat A/S hereby announces the following information received 24 March 2025.
| Details of the person discharging managerial responsibilities/person closely associated | ||
| Name: | Frede Clausen | |
| Reason for the notification: | ||
| Position/status: | Chairman of the board of directors in Cemat A/S | |
| Initial notification/Amendment: | Initial | |
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| Name: | Cemat A/S | |
| LEI: | 213800899MWAZT9KQZ78 | |
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| Description of the financial instrument, type of instrument: | Shares | |
| Identification code: | ISIN DK0010271584 | |
| Nature of the transaction: | Purchase of shares | |
| Price(s): | DKK 319,200 | |
| Volume (s): | 300,000 | |
| Aggregated information: | ||
| 300,000 | |
| DKK 319,200, equivalent to DKK 1.064 per share | |
| Date of the transaction: | 24 March 2025 | |
| Place of the transaction: | Nasdaq Copenhagen, XCSE | |
Cemat A/S
Jaroslaw Pawel Lipinski
CEO
This announcement has been prepared in a Danish-language and an English-language version. In case of doubt, the Danish version prevails.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Euro Manganese Inc.26.3.2025 01:39:11 CET | Press release
Euro Manganese’s Chvaletice Project Designated a Strategic Project under the EU’s Critical Raw Materials Act
Genmab A/S25.3.2025 22:28:05 CET | Press release
Genmab Announces Initiation of Share Buy-Back Program
iTeos Therapeutics Inc.25.3.2025 21:35:00 CET | Press release
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
Evaxion Biotech25.3.2025 21:30:39 CET | Press release
Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting
Zymeworks Inc.25.3.2025 21:30:35 CET | Press release
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom